We do not support your browser. Please take a moment and upgrade to the most recent version of Internet Explorer.
CTSI Directory

André Rogatko, Ph.D. [ Edit Your Profile ]

Work Email Address: Andre.Rogatko@cshs.org

Office Phone Number: 310-423-3316

Work Address:
Samuel Oschin Comprehensive Cancer Institute
Cedars-Sinai Medical Center
116 N. Robertson Blvd Ste 900C
Los Angeles, CA 90048

Cedar-Sinai Medical Center Director, Biostatistics and Bioinformatics

Research Interests

Stats/Methods/Informatics - Biostatistics and/or Biometry; Medicine - Oncology

Ph.D., São Paulo University, São Paulo, Brazil, 1979 - 1983
M.S., São Paulo University, São Paulo, Brazil, 1977 - 1978
B.S., São Paulo University, São Paulo, Brazil, 1973 - 1976


André Rogatko, PhD is Associate Director of the Samuel Oschin Comprehensive Cancer Institute for Biostatistics. Dr. Rogatko came to Cedars-Sinai with substantial experience, including serving as:

-Associate Director of Biostatistics at the Winship Cancer Institute
-Professor in the Department of Biostatistics at The Rollins School of Public Health
-Professor in the Department of Hematology and Oncology at School of Medicine, Emory University
-Chairman of the Department of Biostatistics at the Fox Chase Cancer Center and Director of the Biostatistics Facility. He joined the Fox Chase Cancer Center as Associate Member in 1992 and was promoted to Member with tenure in 1995 and Chairman of the Department of Biostatistics on January 4, 1999
-He has had appointments at the International Agency for Research on Cancer (World Health Organization, Lyon, 1990-1992) and Memorial Sloan-Kettering Cancer Center (1985-1990)

Dr. Rogatko has more than 100 published peer-reviewed articles, book chapters and computer applications in biostatistics and genetic epidemiology and is a recognized expert in adaptive trials in oncology. He has been developing methodologies to improve the design and provide more efficient analytical tools in phase I/II clinical trials. Notably, he developed a new approach for dose escalation in phase I clinical trials, referred to as EWOC (Escalation With Overdose Control). As a consequence of his work, more patients are expected to be treated with therapeutically doses of a promising new agent and fewer patients will be overdosed and suffer from its toxic effects. Dr. Rogatko has proposed a new paradigm for the clinical evaluation of new cancer therapies. It entails adjusting the search for the optimal dose on the basis of measurable patient characteristics that may be predictive of adverse responses to treatment, and extending this search beyond phase I and into phases II and III.

Dr. Rogatko has been developing methodology with applications in the areas of segregation analysis, gene mapping, and risk prediction. He has proposed a method for risk prediction with linked markers, and also developed methods to characterize diagnostic tests with multi-valued outcomes. He also proposed methods to construct meiotic gene maps while controlling the probability of a decision-error and also proposed two diagnostics for the statistical assessment of the Hardy-Weinberg equilibrium.

Dr. Rogatko is also further developing research in Patient Characteristics as Predictors of Toxicity to Cancer Treatment. This research project is the first large scale effort to link genetic, pharmacokinetic, and clinical variables for the prediction of toxicity and response to taxane-based chemotherapy. The expected result of this project is that cancer patients will be: (i) more likely to receive therapeutic doses of promising new agents, (ii) less likely to suffer the deleterious effects of toxic doses, and (iii) promising therapies will become available more rapidly.

Dr. Rogatko earned his doctorate degree in Genetics and Statistics, summa cum laude, from Sao Paulo University in Brazil in 1983.

Parker Kathy P, Bliwise Donald L, Ribeiro Maria, Jain Sanjay R, Vena Catherine I, Kohles-Baker Mary Kay, Rogatko Andre, Xu Zhiheng, Harris Wayne B, Sleep/Wake patterns of individuals with advanced cancer measured by ambulatory polysomnography. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2008; 26(15): 2464-72.
Tighiouart Mourad, Rogatko André, Babb James S, Flexible Bayesian methods for cancer phase I clinical trials. Dose escalation with overdose control. Statistics in medicine. 2005; 24(14): 2183-96.
Rogatko André, Babb James S, Tighiouart Mourad, Khuri Fadlo R, Hudes Gary, New paradigm in dose-finding trials: patient-specific dosing and beyond phase I. Clinical cancer research : an official journal of the American Association for Cancer Research. 2005; 11(15): 5342-6.
Rogatko André, Babb James S, Wang Hao, Slifker Michael J, Hudes Gary R, Patient characteristics compete with dose as predictors of acute treatment toxicity in early phase clinical trials. Clinical cancer research : an official journal of the American Association for Cancer Research. 2004; 10(14): 4645-51.
Borghaei Hossein, Millenson Michael, Schilder Russell, Alden Mitchell, Rogatko Andre, Wang Hao, Padavic-Shaller Kristin, Smith Mitchell R, Phase II study of paclitaxel and estramustine in patients with recurrent and refractory non-Hodgkin lymphoma. Cancer. 2004; 101(9): 2034-41.
Cohen Steven J, Ho Linus, Ranganathan Sulabha, Abbruzzese James L, Alpaugh R Katherine, Beard Mary, Lewis Nancy L, McLaughlin Susan, Rogatko André, Perez-Ruixo Juan J, Thistle Amanda M, Verhaeghe Tom, Wang Hao, Weiner Louis M, Wright John J, Hudes Gary R, Meropol Neal J, Phase II and pharmacodynamic study of the farnesyltransferase inhibitor R115777 as initial therapy in patients with metastatic pancreatic adenocarcinoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2003; 21(7): 1301-6.
Rogatko André, Slifker Michael J, Babb James S, Hardy-Weinberg equilibrium diagnostics. Theoretical population biology. 2002; 62(3): 251-7.

Cite the Grant Number Trial Innovation Network Smart IRB